CYP17A1 and glioblastoma: This abiraterone [324] (CYP17A1 inhibitor)/hydroxamic acid inhibitor also showed a potent antiproliferative effect on GBM both in vitro and in vivo, enhanced ROS production, activated DDR, and reversed TMZ resistance [325].